Dream Finders Home Inc. said in a Dec. 23 Securities and Exchange Commission filing that Chief Operations Officer Doug Moran is transitioning to a nonexecutive officer role with the company.
The Jacksonville-based homebuilder said the transition will enable Moran to better manage his health as he reduces his travel, but gave no other details.
Moran was listed as 52 years old in Dream Finders’ annual proxy statement.
He was one of the two top executives serving as senior vice presidents under founder and CEO Patrick Zalupski. The other is Chief Financial Officer L. Anabel Fernandez.
Moran joined Dream Finders as division president for Northeast Florida in August 2015 and became chief operations officer of the company in January 2017, according to the proxy.
He will take on a newly created role of national president of Dream Finders, the Dec. 23 SEC filing said.
The company said it has begun the process of finding a successor to Moran as COO.
Treace Medical Concepts Inc. hit a bump in the road in May when the maker of surgical products to treat bunions reduced its revenue forecast, sending its stock plummeting.
As investors look to 2025, two analysts issued reports indicating caution about the stock’s recovery in the year ahead.
“On one hand, we remain believers in the Lapiplasty value proposition as Treace’s innovative solution for bunion correction is a clear improvement over legacy solutions that translates to superior outcomes for patients,” J.P. Morgan analyst Lily Lozada said in a Dec. 17 research report.
Lapiplasty is Ponte Vedra-based Treace’s main procedure for treating bunions.
“In addition, the company’s growing portfolio of ancillary products enables it to become a one-stop shop for bunion procedures,” Lozada said.
“On the other, competitive pressures have begun to materialize, which clouds the outlook for the Lapiplasty ramp from here,” she said.
“While the company should be able to more effectively compete once its MIS osteotomy products are on the market, it remains to be determined how well Treace will be able to win back share from its larger orthopedics peers.”
The stock was priced at $17 in its April 2021 initial public offering and traded as high as $37.17 in June 2021.
The stock had fallen back but was trading near $11 in early May, when its reduced forecast sent the stock to a low of $3.92.
The stock traded in a range of $7 to $8 for most of December 2024.
Lozada rates the stock as “neutral” with an $8 price target.
Truist Securities analyst Richard Newitter maintained a “hold” rating on Treace while raising his price target from $7 to $8.40 in a Dec. 18 report on the medical technology industry.
After Duos Technologies Group Inc. added two new business lines in 2024 to its main business of technology for the railroad industry, Ascendiant Capital Markets analyst Edward Woo sees strong potential for its stock.
Jacksonville-based Duos announced the formation of one subsidiary to provide artificial intelligence data centers in rural markets and added another subsidiary to provide energy services.
Woo said in a research note the businesses “have long commercialization challenges ahead, but we believe the approximate billion dollar market potential presents high rewards for the risks,” he said.
Woo maintained his “buy” rating but raised his price target from $6 to $7.50, with the stock trading at $4.10 at the time of his Dec. 16 report.
“This represents significant upside from the current share price and we believe appropriately balances out the high risks with large upside opportunities,” he said.
Cadre Holdings Inc. announced a new credit agreement Dec. 23 that helps the Jacksonville-based maker of safety and security products seek additional acquisition opportunities.
The five-year agreement with a group of banks provides Cadre with up to $590 million in credit.
“This strategic refinancing provides more scale and financial flexibility with favorable terms and extended maturities, enabling Cadre to continue to proactively seek to capitalize on meaningful organic and inorganic growth opportunities,” said CEO Warren Kanders in a news release.
Cadre, which focuses on products for the law enforcement and first responder markets, has grown through acquisitions and Kanders has repeatedly stated his goals of finding new merger targets since the company went public in 2021.
“Cadre’s M&A program is a key component to accelerate long-term growth. We continue to aggressively evaluate a robust pipeline of potential transactions and are tracking well to further grow our platform and enhance our market leadership through M&A,” Kanders said in Cadre’s quarterly conference call Nov. 6, according to a company transcript.